How does inflammation in chronic diseases contribute to anemia?

How does inflammation in chronic diseases contribute to anemia?

• A. It increases iron absorption
• B. It promotes red blood cell production
• C. It inhibits red blood cell production
• D. It destroys red blood cells

Answer: (C)

In chronic diseases, inflammation plays a significant role in the development of anemia, primarily by inhibiting red blood cell production. Inflammatory cytokines produced during chronic inflammatory states can interfere with the normal functioning of erythropoiesis, the process by which red blood cells are produced in the bone marrow. One way this inhibition occurs is through the action of hepcidin, a liver-derived hormone that regulates iron metabolism. During inflammation, increased hepcidin levels can lead to decreased iron availability for erythropoiesis because it limits iron absorption from the intestine and sequesters iron in macrophages, making it unavailable for red blood cell formation. Additionally, inflammatory cytokines may impair the response of erythroid progenitor cells to erythropoietin, a hormone that stimulates red blood cell production. The other options do not accurately describe the relationship between inflammation and anemia in chronic diseases. Iron absorption is often reduced rather than increased; red blood cell production is inhibited rather than promoted; and while there may be some destruction of red blood cells during certain inflammatory processes, the main contribution to anemia in chronic disease is the impairment of production rather than a significant loss of red blood cells.

In chronic diseases, inflammation plays a significant role in the development of anemia, primarily by inhibiting red blood cell production. Inflammatory cytokines produced during chronic inflammatory states can interfere with the normal functioning of erythropoiesis, the process by which red blood cells are produced in the bone marrow.

One way this inhibition occurs is through the action of hepcidin, a liver-derived hormone that regulates iron metabolism. During inflammation, increased hepcidin levels can lead to decreased iron availability for erythropoiesis because it limits iron absorption from the intestine and sequesters iron in macrophages, making it unavailable for red blood cell formation. Additionally, inflammatory cytokines may impair the response of erythroid progenitor cells to erythropoietin, a hormone that stimulates red blood cell production.

The other options do not accurately describe the relationship between inflammation and anemia in chronic diseases. Iron absorption is often reduced rather than increased; red blood cell production is inhibited rather than promoted; and while there may be some destruction of red blood cells during certain inflammatory processes, the main contribution to anemia in chronic disease is the impairment of production rather than a significant loss of red blood cells.